Physician profile
Irina Berlin
NPI 1932169307
$6,464.38
in general payments reported to CMS, 2019-2025
19 companies · $905 in 2025
The $905 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $524 · 2021: $1,196 · 2022: $1,194 · 2023: $907 · 2024: $870 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,682.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,161.13 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $866.04 | 2019-2024 | |
| Abbvie INC. | $789.53 | 2019-2025 | Linzess, Viberzi |
| Ironwood Pharmaceuticals, INC | $528.30 | 2019-2025 | Linzess |
| Ardelyx, INC. | $411.66 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $318.52 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $292.56 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $276.93 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $228.35 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $175.75 | 2024-2025 | Voquezna |
| Allergan, INC. | $96.36 | 2019 | |
| Redhill Biopharma INC. | $79.24 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $68.91 | 2020-2023 | Ocaliva |
| Braintree Laboratories, INC. | $43.13 | 2021-2022 | |
| Vivus LLC | $39.23 | 2021-2023 | Pancreaze |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $26.64 | 2025 | Iqirvo |
| Glaxosmithkline, LLC. | $22.27 | 2019 | |
| Janssen Biotech, INC. | $20.31 | 2022 | |
| Merck Sharp & Dohme LLC | $19.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Berlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.